Drug:
Reaction: ILLNESS
20250101 - 20251231
No. 601 - 700
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 601 | 25076861 |
CA |
46 | 2 |
Crohn^s disease, Illness, Arthralgia, Product storage error, Product administration error, Expired product administered, Inappropriate schedule of product administration, Wrong schedule, |
||||
ADALIMUMAB-RYVK, ADALIMUMAB-RYVK, ADALIMUMAB-RYVK, ADALIMUMAB-RYVK, ADALIMUMAB-RYVK, |
||||
| 602 | 25076940 |
US |
81 | 1 |
Myocardial infarction, Dysuria, Illness, Feeding disorder, Nausea, Decreased appetite, Blood urine present, Diarrhoea, Constipation, Asthenia, Weight decreased, Swelling, Tooth disorder, Memory impairment, Muscle atrophy, Musculoskeletal discomfort, Pain, Infusion related reaction, |
||||
NIVOLUMAB, CABOZANTINIB, CABOZANTINIB, CABOZANTINIB, CABOZANTINIB, DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM, FILM COATED, DICLOFENAC POTASSIUM TABLETS, LEVOTHYROXINE SODIUM, TAMSULOSIN HYDROCHLORIDE, INSULIN DEGLUDEC, |
||||
| 603 | 25077031 |
US |
2 | |
Illness, |
||||
SECUKINUMAB, |
||||
| 604 | 25077092 |
CA |
2 | |
Lower respiratory tract infection, Illness, Back pain, Arthralgia, Nasopharyngitis, |
||||
VEDOLIZUMAB, LEVOTHYROXINE SODIUM, PREDNISONE, |
||||
| 605 | 25077136 |
US |
30 | 2 |
Illness, Product leakage, Nasopharyngitis, Hidradenitis, Condition aggravated, |
||||
SECUKINUMAB, HYDROCORTISONE, CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE 4%, |
||||
| 606 | 25077372 |
GB |
25 | 2 |
Illness, |
||||
METRONIDAZOLE, METRONIDAZOLE TOPICAL, TRANEXAMIC ACID, |
||||
| 607 | 25077381 |
US |
2 | |
Illness, |
||||
MACITENTAN, |
||||
| 608 | 25077440 |
GB |
1 | |
Illness, |
||||
TACROLIMUS, TACROLIMUS OINTMENT 0.1%, TACROLIMUS EXTENDED-RELEASE CAPSULES, PREDNISOLONE, PREDNISOLONE ORAL, PREDNISOLONE ORAL SOLUTION, |
||||
| 609 | 25077703 |
GB |
2 | |
Illness, Nausea, Vomiting, Counterfeit product administered, |
||||
SEMAGLUTIDE, |
||||
| 610 | 25077721 |
US |
58 | 2 |
Cardiac operation, Illness, Hypersensitivity, Nausea, Vomiting, |
||||
ORAL SEMAGLUTIDE, |
||||
| 611 | 25077730 |
US |
71 | 2 |
Nausea, Headache, Abdominal pain upper, Diarrhoea, Abdominal discomfort, Retching, Cold sweat, Initial insomnia, Hot flush, Illness, |
||||
SEMAGLUTIDE, INSULIN DEGLUDEC, ABALOPARATIDE, ACETAMINOPHEN, ACETAMINOPHEN ORAL SOLUTION, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, DIPHENHYDRAMINE HCL, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, ATENOLOL, DICLOFENAC, DICLOFENAC SODIUM, DOXEPIN HYDROCHLORIDE, DOXEPN HYDROCHLORIDE, FENOFIBRATE, FLUOXETINE HYDROCHLORIDE, FLUOXETINE, INSULIN LISPRO, HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE, LEVOTHYROXINE, PANTOPRAZOLE, VALACYCLOVIR, VALACYCLOVIR HYDROCHLORIDE, |
||||
| 612 | 25077824 |
US |
||
Illness, Nausea, |
||||
TIRZEPATIDE, |
||||
| 613 | 25077979 |
US |
76 | 2 |
Illness, Therapeutic product effect incomplete, |
||||
DEUTETRABENAZINE, |
||||
| 614 | 25078021 |
US |
||
Device malfunction, Illness, Drug dose omission by device, |
||||
INFLIXIMAB-DYYB, |
||||
| 615 | 25078029 |
US |
||
Illness, |
||||
LUTETIUM LU 177 DOTATATE, |
||||
| 616 | 25078257 |
US |
1 | |
Fistula, Ulcer, Drug ineffective, Illness, |
||||
UPADACITINIB, |
||||
| 617 | 25078353 |
CA |
35 | 2 |
Anxiety, Asthma, Burning sensation, Chest discomfort, Chest pain, Cough, Crying, Dehydration, Depression, Dizziness, Dyspnoea, Emphysema, Feeling cold, Fluid retention, Forced expiratory volume decreased, Hot flush, Hypoventilation, Illness, Injection site pain, Lower respiratory tract infection, Malaise, Influenza, Mental disorder, Nasal congestion, Nasopharyngitis, Nausea, Obstructive airways disorder, Oropharyngeal pain, Pain, Pain in extremity, Peripheral swelling, Pneumonia, Productive cough, Pruritus, Rhinorrhoea, Seasonal allergy, Stress, Suicidal ideation, Syncope, Vomiting, Weight decreased, Weight increased, Wheezing, |
||||
OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, ESCITALOPRAM, ESCITALOPRAM OXALATE, ESCITSLOPRAM, QUETIAPINE FUMARATE, QUETIAPINE, VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE, |
||||
| 618 | 25078409 |
US |
67 | 1 |
Illness, |
||||
TUCATINIB, |
||||
| 619 | 25078519 |
US |
||
Illness, Malaise, Back pain, Fatigue, |
||||
GIVOSIRAN SODIUM, HEMIN, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, OXYCODONE HYDROCHLORIDE AND ACETAMINOPHEN, EPINEPHRINE, ADRENALINUM, |
||||
| 620 | 25078579 |
US |
54 | 2 |
COVID-19, Illness, |
||||
OCRELIZUMAB, |
||||
| 621 | 25078629 |
US |
64 | 2 |
Dry skin, Skin haemorrhage, Blister, Illness, Pruritus, Injection site pain, Dry eye, Drug ineffective, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 622 | 25078816 |
US |
64 | 2 |
Illness, Malaise, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 623 | 25079230 |
CA |
62 | |
Headache, Hypertension, Abdominal discomfort, Infection, Influenza, Lung disorder, Lung hyperinflation, Illness, Obstructive airways disorder, Productive cough, Respiratory disorder, Snoring, Sputum discoloured, Wheezing, Asthma, Full blood count abnormal, Breath sounds abnormal, Bronchiectasis, Dyspnoea, Flatulence, Heart rate increased, Therapeutic product effect incomplete, Drug ineffective, |
||||
FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE, MEPOLIZUMAB, MEPOLIZUMAB, ALBUTEROL SULFATE, FLUTICASONE FUROATE, AZITHROMYCIN, AZITHROMYCIN MONOHYDRATE, AZITHROMYCIN DIHYDRATE, PREDNISONE, PREDNISONE, TIOTROPIUM BROMIDE, IPRATROPIUM BROMIDE, ALBUTEROL SULFATE, |
||||
| 624 | 25079477 |
US |
78 | 1 |
Anaemia, Illness, Dementia, |
||||
VOXELOTOR, |
||||
| 625 | 25079512 |
US |
||
Immunodeficiency, Illness, Lung disorder, Wrong technique in device usage process, Overdose, Drug ineffective, Product use in unapproved indication, Product complaint, |
||||
FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE, FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE, FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE, FLUTICASONE PROPIONATE AND SALMETEROL, FLUTICASONE PROPIONATE AND SALMETEROL, |
||||
| 626 | 25079699 |
US |
62 | 2 |
Neutrophil count decreased, Illness, Off label use, |
||||
| 627 | 25079725 |
|||
Illness, |
||||
RUXOLITINIB, |
||||
| 628 | 25079746 |
US |
2 | |
Heavy menstrual bleeding, Illness, |
||||
ETONOGESTREL, ETONOGESTREL, |
||||
| 629 | 25079776 |
US |
73 | 2 |
Illness, |
||||
ABATACEPT, |
||||
| 630 | 25079910 |
US |
52 | 1 |
Illness, |
||||
LENALIDOMIDE, |
||||
| 631 | 25080005 |
US |
2 | |
Illness, |
||||
MEPOLIZUMAB, |
||||
| 632 | 25080047 |
US |
2 | |
Illness, Off label use, |
||||
ALENDRONATE SODIUM, ALENDRONATE SODIUM TABLET, FLUDROCORTISONE ACETATE, HYDROXYZINE, ALBUTEROL SULFATE, AZITHROMYCIN, AZITHROMYCIN MONOHYDRATE, AZITHROMYCIN DIHYDRATE, THIAMINE HYDROCHLORIDE, RIBOFLAVIN 5 PHOSPHATE SODIUM, DEXPANTHENOL AND NIACINAMIDE, DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AND AMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE SULFATE AND AMPHETAMINE ASPARTATE, GABAPENTIN, LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM ANHYDROUS, DESVENLAFAXINE SUCCINATE, MIRTAZAPINE, |
||||
| 633 | 25080056 |
US |
68 | 2 |
Endometrial cancer recurrent, Anaemia, Cortisol decreased, Blood test abnormal, Hospitalisation, Product use issue, Illness, |
||||
PEMBROLIZUMAB, |
||||
| 634 | 25080195 |
US |
||
Illness, Nasopharyngitis, Weight increased, |
||||
LARONIDASE, |
||||
| 635 | 25080235 |
US |
76 | 2 |
Influenza, Feeling abnormal, Illness, Aphonia, Unevaluable event, |
||||
RISANKIZUMAB-RZAA, RISANKIZUMAB-RZAA, |
||||
| 636 | 25083542 |
64 | 1 | |
Illness, Therapy interrupted, |
||||
ETANERCEPT, |
||||
| 637 | 25071704 |
US |
||
Illness, |
||||
BUROSUMAB, BUROSUMAB, |
||||
| 638 | 25071771 |
US |
77 | 2 |
Pruritus, Illness, Hypoacusis, Product substitution issue, |
||||
VALSARTAN AND HYDROCHLOROTHIAZIDE, |
||||
| 639 | 25071837 |
US |
16 | 1 |
Illness, Injection site pain, |
||||
DUPILUMAB, |
||||
| 640 | 25071838 |
US |
2 | |
Lung disorder, Illness, |
||||
DUPILUMAB, |
||||
| 641 | 25071866 |
ZA |
5 | 2 |
Illness, |
||||
PALIVIZUMAB, |
||||
| 642 | 25072010 |
US |
26 | 1 |
Decreased immune responsiveness, Influenza, Coronavirus infection, Herpes zoster, Weight decreased, Illness, Asthenia, |
||||
INFLIXIMAB, |
||||
| 643 | 25072120 |
US |
1 | |
Illness, |
||||
PIMAVANSERIN TARTRATE, |
||||
| 644 | 25072197 |
US |
2 | |
Gait disturbance, Infection, Illness, |
||||
EPOPROSTENOL, EPOPROSTENOL, EPOPROSTENOL, SILDENAFIL CITRATE, SILDENAFIL, EPOPROSTENOL, |
||||
| 645 | 25072334 |
US |
52 | 1 |
Illness, |
||||
ABATACEPT, |
||||
| 646 | 25072354 |
CA |
61 | 2 |
Sinusitis, Asthma, Blood pressure increased, Bronchitis, Contusion, Cough, Dyspnoea, Dyspnoea exertional, Fall, Gait disturbance, Illness, Influenza, Injection site erythema, Injection site pain, Injection site pruritus, Injection site swelling, Limb injury, Malaise, Nasopharyngitis, Oxygen saturation decreased, Pain in extremity, Pneumonia, Pulmonary congestion, Rhinitis, Scratch, Seasonal allergy, Speech disorder, Viral infection, Wheezing, Product availability issue, Wrong technique in product usage process, |
||||
OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, CICLESONIDE, CETIRIZINE HYDROCHLORIDE, CETIRIZINE, CETIRIZINE HYDROCHLORIDE TABLETS, CETIRIZINE HYDROCHLORIDE ALLERGY, DESOXIMETASONE, MOXIFLOXACIN HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE OPHTHALMIC, ALBUTEROL SULFATE, ALBUTEROL, GLYCOPYRROLATE, MONTELUKAST SODIUM, TIOTROPIUM BROMIDE, TOBRAMYCIN, TOBRAMYCIN SULFATE, TOBRAMYCIN SOLUTION, ALBUTEROL SULFATE, |
||||
| 647 | 25072697 |
US |
76 | 1 |
Illness, Nasopharyngitis, |
||||
INSULIN GLARGINE, |
||||
| 648 | 25072740 |
US |
55 | 2 |
Illness, Endodontic procedure, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 649 | 25072836 |
IL |
2 | |
Death, Malaise, Illness, |
||||
TALQUETAMAB, |
||||
| 650 | 25072837 |
CA |
65 | 2 |
Angina pectoris, Anaemia, Arthralgia, Arthritis, Balance disorder, Body temperature decreased, Bone pain, Bronchitis, Contusion, Cough, Deafness transitory, Dizziness, Dyspepsia, Ear discomfort, Fatigue, Feeling abnormal, Feeling hot, Frustration tolerance decreased, Gait disturbance, Headache, Hyperhidrosis, Illness, Influenza, Irritability, Joint swelling, Meniere^s disease, Oliguria, Oropharyngeal pain, Pain, Pain in extremity, Paraesthesia, Paraesthesia oral, Peripheral swelling, Pneumonia, Respiratory fume inhalation disorder, Sense of oppression, Sensitivity to weather change, Sinusitis, Sputum discoloured, Tinnitus, Tumour compression, Vertigo, Viral infection, Visual impairment, |
||||
OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, FLUTICASONE FUROATE, BUDESONIDE, FUROSEMIDE, DIMENHYDRINATE, ATORVASTATIN CALCIUM, METFORMIN, METFORMIN ER 500 MG, METFORMIN ER 750 MG, PANTOPRAZOLE SODIUM, PANTOPRAZOLE, PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDE, PANTOPRAZOLE SODIUM INJECTION, PREDNISONE, MONTELUKAST SODIUM, ALBUTEROL SULFATE, |
||||
| 651 | 25072978 |
US |
||
Illness, |
||||
RAVULIZUMAB, |
||||
| 652 | 25072999 |
US |
||
Illness, |
||||
TOPIRAMATE, TOPIRAMATE SPINKLE, |
||||
| 653 | 25073113 |
US |
49 | 2 |
Treatment failure, Disturbance in attention, Chills, Visual impairment, Dry mouth, Gait disturbance, Weight decreased, Yellow skin, Illness, Vitamin D deficiency, Musculoskeletal stiffness, Cough, Flushing, |
||||
DIROXIMEL FUMARATE, DIROXIMEL FUMARATE, DIROXIMEL FUMARATE, |
||||
| 654 | 25073151 |
US |
||
Illness, Wrong technique in product usage process, |
||||
TIRZEPATIDE, |
||||
| 655 | 25073212 |
US |
||
Illness, Retching, |
||||
XANOMELINE AND TROSPIUM CHLORIDE, |
||||
| 656 | 25073214 |
US |
1 | |
Illness, Product dose omission in error, |
||||
DUPILUMAB, ALBUTEROL SULFATE, FLUTICASONE FUROATE AND VILANTEROL TRIFENATATE, HYDROCHLOROTHIAZIDE, LEVOTHYROXINE, POTASSIUM CHLORIDE, POTASSIUM CHLORIDE EXTENDED-RELEASE, POTASSIUM CHLORIDE, DEXTROSE MONOHYDRATE, POTASSIUM CHLORIDE ORAL, |
||||
| 657 | 25073250 |
HU |
2 | |
Illness, |
||||
OSELTAMIVIR PHOSPHATE, |
||||
| 658 | 25073290 |
US |
11 | 1 |
Illness, Rash, |
||||
DUPILUMAB, |
||||
| 659 | 25073392 |
US |
64 | 2 |
Death, Respiratory distress, Secretion discharge, Drug resistance, Diarrhoea, Bronchospasm, Cough, Illness, Dyspnoea, Off label use, |
||||
AMIKACIN, AMIKACIN, AMIKACIN, AMIKACIN, AMIKACIN, AMIKACIN, |
||||
| 660 | 25073585 |
US |
2 | |
Mast cell activation syndrome, Medical procedure, Illness, Eczema, Off label use, Product administration interrupted, |
||||
SODIUM OXYBATE, SODIUM OXYBATE, SODIUM OXYBATE, SODIUM OXYBATE, CETIRIZINE HCL, CETIRIZINE, CLONAZEPAM, GABAPENTIN, |
||||
| 661 | 25073589 |
US |
2 | |
Prescribed underdose, Illness, |
||||
NATALIZUMAB, NATALIZUMAB, |
||||
| 662 | 25073592 |
US |
1 | |
Illness, |
||||
DIROXIMEL FUMARATE, METFORMIN HYDROCHLORIDE, METFORMIN, METFORMIN HYDROCHLORIDE EXTENDED-RELEASE TABLETS, METFORMIN HYDROCHLORIDE TABLET, METFORMIN HYDROCHLORIDE TABLETS, GLIPIZIDE, AMLODIPINE BESYLATE, HYDROCHLOROTHIAZIDE, ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM, FILM COATED, ERGOCALCIFEROL, SITAGLIPTIN, GUAIFENESIN, VITAMIN C, VITAMIN E, CREAM, CINNAMON, METOPROLOL TARTRATE, METOROPROLOL TARTRATE, METOPROLOL, DAPAGLIFLOZIN, |
||||
| 663 | 25073593 |
CA |
26 | 2 |
Urticaria, Anaphylactic reaction, Angioedema, Blood pressure increased, COVID-19, Condition aggravated, Contusion, Cough, Erythema, Fatigue, Headache, Heart rate increased, Illness, Immunodeficiency, Injection site pain, Insomnia, Ligament sprain, Loss of consciousness, Malaise, Menstrual disorder, Migraine, Musculoskeletal stiffness, Nasopharyngitis, Obstructive airways disorder, Off label use, Oropharyngeal pain, Pain, Peripheral swelling, Pharyngitis streptococcal, Pruritus, Respiratory arrest, Sensitivity to weather change, Sinus congestion, Sinusitis, Skin burning sensation, Sleep apnoea syndrome, Stress, Swelling, |
||||
OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, DUPILUMAB, GABAPENTIN, MEDROXYPROGESTERONE ACETATE, PREDNISONE, BUPROPION HYDROCHLORIDE, DESVENLAFAXINE, DESVENLAFAXINE SUCCINATE, |
||||
| 664 | 25073601 |
US |
36 | 2 |
Systemic lupus erythematosus, Weight decreased, Postural orthostatic tachycardia syndrome, Dizziness, Nausea, Abdominal discomfort, Hyperhidrosis, Disability, Vomiting, Illness, Diarrhoea, Dyspepsia, Constipation, Treatment noncompliance, Product container issue, Product administration interrupted, Intentional dose omission, |
||||
CALCIUM, MAGNESIUM, POTASSIUM, AND SODIUM OXYBATES, CALCIUM, MAGNESIUM, POTASSIUM, AND SODIUM OXYBATES, CALCIUM, MAGNESIUM, POTASSIUM, AND SODIUM OXYBATES, CALCIUM, MAGNESIUM, POTASSIUM, AND SODIUM OXYBATES, CALCIUM, MAGNESIUM, POTASSIUM, AND SODIUM OXYBATES, CALCIUM, MAGNESIUM, POTASSIUM, AND SODIUM OXYBATES, BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE (XL), |
||||
| 665 | 25073745 |
US |
59 | 2 |
Acute kidney injury, Illness, Influenza, Norovirus infection, Vomiting, Abdominal distension, Nausea, Decreased appetite, Gastroenteritis viral, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 666 | 25073823 |
US |
57 | 2 |
Device difficult to use, Illness, Respiratory disorder, Drug dose omission by device, |
||||
ETANERCEPT, ETANERCEPT, ETANERCEPT, |
||||
| 667 | 25073980 |
US |
66 | 2 |
Illness, Gait disturbance, Nasopharyngitis, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 668 | 25073982 |
US |
2 | |
Illness, Drug hypersensitivity, Drug ineffective, |
||||
SARILUMAB, |
||||
| 669 | 25074033 |
US |
2 | |
Illness, Vomiting, Product dose omission issue, |
||||
TROFINETIDE, |
||||
| 670 | 25074237 |
CA |
74 | 2 |
Diabetes mellitus, Asthmatic crisis, Weight decreased, Wheezing, Arthralgia, Stress, Blood pressure systolic increased, Cough, Sensitivity to weather change, Illness, Respiratory rate increased, Injection site scab, Peripheral swelling, Productive cough, Injection site erythema, Hypersensitivity, Asthma, Wrong technique in product usage process, Drug ineffective, |
||||
OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, DICLOFENAC, DICLOFENAC SODIUM, DICLOFENAC, DICLOFENAC SODIUM, DICLOFENAC, DICLOFENAC SODIUM, PANTOPRAZOLE, PANTOPRAZOLE, PANTOPRAZOLE, PANTOPRAZOLE, PANTOPRAZOLE, PANTOPRAZOLE, PANTOPRAZOLE, PANTOPRAZOLE, VALSARTAN, VALSARTAN, VALSARTAN, VALSARTAN, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, FLUTICASONE FUROATE, FLUTICASONE FUROATE, ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM, MONTELUKAST SODIUM, MONTELUKAST SODIUM, TIOTROPIUM BROMIDE, TIOTROPIUM BROMIDE, ALBUTEROL SULFATE, ALBUTEROL SULFATE, |
||||
| 671 | 25074283 |
US |
||
Illness, Nausea, Influenza, Product dose omission issue, Underdose, |
||||
OLAPARIB, |
||||
| 672 | 25074375 |
CA |
55 | 2 |
Pneumonia, Dyspnoea, Immunodeficiency, Lower respiratory tract infection, Tinnitus, Feeling hot, Agitation, Fatigue, Anxiety, Mobility decreased, Gait disturbance, Joint swelling, Arthralgia, Illness, Therapeutic product effect incomplete, Pharyngitis, Ear infection, Insomnia, |
||||
SECUKINUMAB, SECUKINUMAB, SECUKINUMAB, SECUKINUMAB, SECUKINUMAB, SECUKINUMAB, SECUKINUMAB, SECUKINUMAB, SECUKINUMAB, METHOTREXATE, METHOTREXATE SODIUM, DOXYCYCLINE, DOXYCYCLINE HYCLATE, LEFLUNOMIDE, SULFASALAZINE, ERGOCALCIFEROL, NAPROXEN, NAPROXEN SODIUM, ACETAMINOPHEN, GUAIFENESIN, AND PHENYLEPHRINE HYDROCHLORIDE, ACETAMINOPHEN, ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE, ESOMEPRAZOLE MAGNESIUM DELAYED RELEASE CAPSULES, LORAZEPAM, SULFAMETHOXAZOLE AND TRIMETHOPRIM, TERBINAFINE HYDROCHLORIDE, CIPROFLOXACIN AND DEXAMETHASONE, CITALOPRAM, CITALOPRAM HYDROBROMIDE, PREDNISONE, AMOXICILLIN, TRIAZOLAM, CEFUROXIME AXETIL, NITROFURANTOIN MONOHYDRATE/MACROCRYSTALLINE, METFORMIN HYDROCHLORIDE, METFORMIN, METFORMIN HYDROCHLORIDE EXTENDED-RELEASE TABLETS, METFORMIN HYDROCHLORIDE TABLET, METFORMIN HYDROCHLORIDE TABLETS, LORAZEPAM, AMITRIPTYLINE HYDROCHLORIDE, METHYLPREDNISOLONE ACETATE, PENICILLIN V POTASSIUM, ERGOCALCIFEROL, CLINDAMYCIN PHOSPHATE, CLINDAMYCIN, METRONIDAZOLE, METRONIDAZOLE TOPICAL, SEMAGLUTIDE, |
||||
| 673 | 25074581 |
US |
||
Illness, |
||||
APREMILAST, |
||||
| 674 | 25074687 |
IN |
67 | 1 |
Off label use, Thrombocytopenia, Eosinophilia, Haemoglobin decreased, Haematocrit decreased, Blood creatinine decreased, Bilirubin conjugated increased, Blood glucose increased, Spinal osteoarthritis, Oesophageal disorder, Gastric ulcer, Red blood cell count decreased, White blood cell count decreased, Monocyte count increased, Normochromic normocytic anaemia, Monocytosis, Melaena, Pulmonary mass, Hepatic lesion, Blood bilirubin increased, Glycosylated haemoglobin increased, Illness, |
||||
ATEZOLIZUMAB, BEVACIZUMAB, BEVACIZUMAB, |
||||
| 675 | 25075199 |
CA |
33 | 2 |
Off label use, Pregnancy, Malaise, Feeling guilty, Depressed mood, Illness, |
||||
VEDOLIZUMAB, VEDOLIZUMAB, CITALOPRAM, CITALOPRAM HYDROBROMIDE, QUETIAPINE, QUETIAPINE EXTENDED-RELEASE, |
||||
| 676 | 25075223 |
US |
53 | 1 |
Brain fog, Illness, |
||||
DUPILUMAB, |
||||
| 677 | 25075324 |
JP |
||
Illness, |
||||
ARIPIPRAZOLE, |
||||
| 678 | 25075350 |
US |
1 | |
Illness, Psoriasis, |
||||
| 679 | 25075364 |
US |
85 | 2 |
Illness, Pain, |
||||
TOFACITINIB, |
||||
| 680 | 25075450 |
US |
35 | 2 |
Atypical pneumonia, Device malfunction, Needle issue, Drug dose omission by device, Illness, Enteritis, Epigastric discomfort, Injection site pain, Fatigue, Product knowledge deficit, Device leakage, |
||||
OFATUMUMAB, OFATUMUMAB, PROPRANOLOL HYDROCHLORIDE, |
||||
| 681 | 25075462 |
US |
||
Renal failure, Weight decreased, Illness, |
||||
TIRZEPATIDE, |
||||
| 682 | 25075609 |
US |
65 | 2 |
Cataract, Pneumonia, COVID-19, Memory impairment, Illness, |
||||
TOFACITINIB, |
||||
| 683 | 25075757 |
US |
||
Illness, Movement disorder, |
||||
BUROSUMAB, |
||||
| 684 | 25075843 |
US |
||
Illness, Drug dose omission by device, Device delivery system issue, Device mechanical issue, |
||||
ALBUTEROL SULFATE, ALBUTEROL, |
||||
| 685 | 25075917 |
US |
1 | |
Illness, Product dose omission issue, |
||||
USTEKINUMAB, |
||||
| 686 | 25076315 |
AE |
55 | 1 |
Illness, Ventricular tachycardia, |
||||
SACUBITRIL AND VALSARTAN, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM, FILM COATED, BISOPROLOL FUMARATE, CLOPIDOGREL BISULFATE, DUTASTERIDE, EZETIMIBE, FUROSEMIDE, PANTOPRAZOLE SODIUM, PANTOPRAZOLE, PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDE, PANTOPRAZOLE SODIUM INJECTION, PENTOXIFYLLINE, SPIRONOLACTONE, TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE, |
||||
| 687 | 25076392 |
US |
62 | 2 |
Injury, Illness, |
||||
TOFACITINIB, TOFACITINIB, |
||||
| 688 | 25076454 |
GB |
2 | |
Abdominal pain upper, Alanine aminotransferase increased, Illness, |
||||
TIRZEPATIDE, |
||||
| 689 | 25076477 |
US |
62 | 2 |
Illness, |
||||
ABATACEPT, |
||||
| 690 | 25076502 |
US |
77 | 2 |
Illness, Nasopharyngitis, Speech disorder, |
||||
LENALIDOMIDE, |
||||
| 691 | 25076586 |
US |
1 | |
Illness, |
||||
NILOTINIB, |
||||
| 692 | 25076722 |
CA |
61 | 2 |
Illness, Pneumonia, Drug ineffective, |
||||
ADALIMUMAB, ADALIMUMAB-FKJP, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, CIPROFLOXACIN HYDROCHLORIDE, METHOTREXATE, METHOTREXATE SODIUM, RAMIPRIL, LEVOTHYROXINE SODIUM, |
||||
| 693 | 25076726 |
US |
2 | |
Illness, |
||||
PEGLOTICASE, |
||||
| 694 | 25066083 |
US |
1 | |
Illness, Malaise, Therapy interrupted, Product dose omission in error, Off label use, |
||||
MYCOPHENOLIC ACID, MYCOPHENILIC ACID, |
||||
| 695 | 25066139 |
US |
2 | |
Wrist surgery, Illness, Candida infection, Throat tightness, Dyspnoea, Headache, |
||||
ESTRADIOL, DIPHENHYDRAMINE HYDROCHLORIDE, |
||||
| 696 | 25066224 |
CA |
70 | 2 |
Back injury, Blood pressure systolic increased, Body temperature decreased, Concomitant disease aggravated, Coronary artery occlusion, Discomfort, Drug hypersensitivity, Fibromyalgia, Asthenia, Gangrene, Illness, Injection site bruising, Injection site mass, Injection site pain, Malaise, Migraine, Muscle spasms, Overgrowth bacterial, Pain, Post procedural diarrhoea, Procedural pain, Influenza, Irritable bowel syndrome, Hypertension, Abdominal pain upper, Norovirus infection, Insomnia, Diarrhoea, Nausea, Urticaria, Vomiting, |
||||
AMOXICILLIN, METOCLOPRAMIDE HYDROCHLORIDE, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, AMLODIPINE, CETIRIZINE HYDROCHLORIDE, CETIRIZINE, CETIRIZINE HYDROCHLORIDE TABLETS, CETIRIZINE HYDROCHLORIDE ALLERGY, DARIFENACIN HYDROBROMIDE, ESOMEPRAZOLE, ESOMEPRAZOLE MAGNESIUM, FAMOTIDINE, METOPROLOL TARTRATE, METOPROLOL, NABILONE, RAMIPRIL, SPIRONOLACTONE, |
||||
| 697 | 25066285 |
US |
19 | 2 |
Product availability issue, Illness, Inappropriate schedule of product administration, |
||||
SECUKINUMAB, |
||||
| 698 | 25066314 |
US |
69 | 2 |
Illness, Vomiting, |
||||
DULAGLUTIDE, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, METFORMIN, METFORMIN ER 500 MG, METFORMIN ER 750 MG, |
||||
| 699 | 25066455 |
US |
||
Facial paralysis, Headache, Illness, Skin temperature decreased, Vision blurred, |
||||
| 700 | 25066506 |
ZA |
2 | |
Illness, |
||||
PALIVIZUMAB, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2025-04-28